• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

光热治疗联合 CD137 激动剂可改善 SM1 黑色素瘤模型的存活率而无肝毒性。

Photothermal therapy co-localized with CD137 agonism improves survival in an SM1 melanoma model without hepatotoxicity.

机构信息

Integrated Biomedical Sciences Program, School of Medicine & Health Sciences, George Washington University, WA 20037, USA.

The George Washington Cancer Center, George Washington University, WA 20052, USA.

出版信息

Nanomedicine (Lond). 2024;19(25):2049-2064. doi: 10.1080/17435889.2024.2389770. Epub 2024 Sep 3.

DOI:10.1080/17435889.2024.2389770
PMID:39225150
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11485692/
Abstract

We investigate combining Prussian Blue nanoparticles (PBNPs), as photothermal therapy (PTT) agents, with agonistic CD137 antibodies (αCD137) on a single nanoparticle platform to deliver non-toxic, anti-tumor efficacy in SM1 murine melanoma. We electrostatically coated PBNPs with αCD137 (αCD137-PBNPs) and quantified their physicochemical characteristics, photothermal and co-stimulatory capabilities. Next, we tested the efficacy and hepatotoxicity of PTT using αCD137-PBNPs (αCD137-PBNP-PTT) in SM1 tumor-bearing mice. The αCD137-PBNPs retained both the photothermal and agonistic properties of the PBNPs and αCD137, respectively. , SM1 tumor-bearing mice treated with αCD137-PBNP-PTT exhibited a significantly higher survival rate (50%) without hepatotoxicity, compared with control treatments. These data suggest the potential utility of co-localizing PBNP-PTT with αCD137-based agonism as a novel combination nanomedicine.

摘要

我们研究了将普鲁士蓝纳米颗粒 (PBNPs) 作为光热治疗 (PTT) 剂与激动型 CD137 抗体 (αCD137) 结合在单个纳米颗粒平台上，以在 SM1 小鼠黑色素瘤中提供非毒性、抗肿瘤功效。我们通过静电涂层将 PBNPs 与 αCD137（αCD137-PBNPs）结合，并量化了它们的物理化学特性、光热和共刺激能力。接下来，我们在 SM1 荷瘤小鼠中测试了 PTT 使用 αCD137-PBNPs（αCD137-PBNP-PTT）的疗效和肝毒性。αCD137-PBNPs 分别保留了 PBNPs 和 αCD137 的光热和激动特性。与对照治疗相比，用 αCD137-PBNP-PTT 治疗的 SM1 荷瘤小鼠的存活率（50%）显著提高，且没有肝毒性。这些数据表明，将 PBNP-PTT 与基于 αCD137 的激动剂共定位作为一种新型联合纳米医学具有潜在的应用价值。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d48/11485692/eac889ae0aa8/INNM_A_2389770_F0007_C.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d48/11485692/034b8046900b/INNM_A_2389770_F0001_C.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d48/11485692/56f6abbda116/INNM_A_2389770_F0002_C.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d48/11485692/a87801cb077f/INNM_A_2389770_F0003_C.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d48/11485692/28ffc4a26b59/INNM_A_2389770_F0004_C.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d48/11485692/52115316f94e/INNM_A_2389770_F0005_C.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d48/11485692/cfbe121e8b37/INNM_A_2389770_F0006_C.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d48/11485692/eac889ae0aa8/INNM_A_2389770_F0007_C.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d48/11485692/034b8046900b/INNM_A_2389770_F0001_C.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d48/11485692/56f6abbda116/INNM_A_2389770_F0002_C.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d48/11485692/a87801cb077f/INNM_A_2389770_F0003_C.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d48/11485692/28ffc4a26b59/INNM_A_2389770_F0004_C.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d48/11485692/52115316f94e/INNM_A_2389770_F0005_C.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d48/11485692/cfbe121e8b37/INNM_A_2389770_F0006_C.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d48/11485692/eac889ae0aa8/INNM_A_2389770_F0007_C.jpg

相似文献

1
Photothermal therapy co-localized with CD137 agonism improves survival in an SM1 melanoma model without hepatotoxicity.光热治疗联合 CD137 激动剂可改善 SM1 黑色素瘤模型的存活率而无肝毒性。
Nanomedicine (Lond). 2024;19(25):2049-2064. doi: 10.1080/17435889.2024.2389770. Epub 2024 Sep 3.
2
CD137 agonist potentiates the abscopal efficacy of nanoparticle-based photothermal therapy for melanoma.CD137激动剂增强基于纳米颗粒的光热疗法对黑色素瘤的远隔效应。
Nano Res. 2022 Mar;15(3):2300-2314. doi: 10.1007/s12274-021-3813-1. Epub 2021 Oct 12.
3
Prussian blue nanoparticle-based antigenicity and adjuvanticity trigger robust antitumor immune responses against neuroblastoma.普鲁士蓝纳米颗粒的抗原性和佐剂活性引发针对神经母细胞瘤的强大抗肿瘤免疫反应。
Biomater Sci. 2019 Apr 23;7(5):1875-1887. doi: 10.1039/c8bm01553h.
4
Conjugating Prussian blue nanoparticles onto antigen-specific T cells as a combined nanoimmunotherapy.将普鲁士蓝纳米颗粒偶联到抗原特异性T细胞上作为一种联合纳米免疫疗法。
Nanomedicine (Lond). 2016 Jul;11(14):1759-67. doi: 10.2217/nnm-2016-0160. Epub 2016 Jul 7.
5
Prussian blue nanoparticle-based photothermal therapy combined with checkpoint inhibition for photothermal immunotherapy of neuroblastoma.基于普鲁士蓝纳米颗粒的光热疗法联合检查点抑制用于神经母细胞瘤的光热免疫治疗
Nanomedicine. 2017 Feb;13(2):771-781. doi: 10.1016/j.nano.2016.10.015. Epub 2016 Nov 5.
6
Nucleolin-targeted doxorubicin and ICG co-loaded theranostic lipopolymersome for photothermal-chemotherapy of melanoma in vitro and in vivo.用于黑色素瘤体外和体内光热化疗的核仁素靶向阿霉素与吲哚菁绿共载诊疗型脂质聚合物囊泡
Eur J Pharm Biopharm. 2024 Sep;202:114411. doi: 10.1016/j.ejpb.2024.114411. Epub 2024 Jul 14.
7
CD137 agonist-based combination immunotherapy enhances activated, effector memory T cells and prolongs survival in pancreatic adenocarcinoma.基于CD137激动剂的联合免疫疗法可增强活化的效应记忆T细胞，并延长胰腺癌患者的生存期。
Cancer Lett. 2021 Feb 28;499:99-108. doi: 10.1016/j.canlet.2020.11.041. Epub 2020 Nov 30.
8
Self-synergistic effect of Prussian blue nanoparticles for cancer therapy: driving photothermal therapy and reducing hyperthermia-induced side effects.普鲁士蓝纳米颗粒在癌症治疗中的自协同效应：驱动光热治疗并减少高热诱导的副作用。
J Nanobiotechnology. 2021 May 4;19(1):126. doi: 10.1186/s12951-021-00819-2.
9
Carbon Dots/Prussian Blue Satellite/Core Nanocomposites for Optical Imaging and Photothermal Therapy.碳点/普鲁士蓝卫星/核纳米复合材料用于光学成像和光热治疗。
ACS Appl Mater Interfaces. 2018 Jan 10;10(1):1084-1092. doi: 10.1021/acsami.7b14972. Epub 2017 Dec 27.
10
Anti-Fn14-Conjugated Prussian Blue Nanoparticles as a Targeted Photothermal Therapy Agent for Glioblastoma.抗Fn14共轭普鲁士蓝纳米颗粒作为胶质母细胞瘤的靶向光热治疗剂
Nanomaterials (Basel). 2022 Aug 1;12(15):2645. doi: 10.3390/nano12152645.

引用本文的文献

1
Protein-based nanoparticles for antimicrobial and cancer therapy: implications for public health.用于抗菌和癌症治疗的蛋白质基纳米颗粒：对公共卫生的影响。
RSC Adv. 2025 May 8;15(19):14966-15016. doi: 10.1039/d5ra01427a. eCollection 2025 May 6.
2
Multidimensional applications of prussian blue-based nanoparticles in cancer immunotherapy.基于普鲁士蓝的纳米颗粒在癌症免疫治疗中的多维应用。
J Nanobiotechnology. 2025 Mar 3;23(1):161. doi: 10.1186/s12951-025-03236-x.

本文引用的文献

1
ATOR-1017 (evunzekibart), an Fc-gamma receptor conditional 4-1BB agonist designed for optimal safety and efficacy, activates exhausted T cells in combination with anti-PD-1.ATOR-1017（依维莫司，evinzumab），一种 Fc-γ 受体条件性 4-1BB 激动剂，旨在实现最佳的安全性和疗效，与抗 PD-1 联合使用可激活耗竭的 T 细胞。
Cancer Immunol Immunother. 2023 Dec;72(12):4145-4159. doi: 10.1007/s00262-023-03548-7. Epub 2023 Oct 5.
2
Engineered tumor-specific T cells using immunostimulatory photothermal nanoparticles.利用免疫刺激光热纳米颗粒工程化的肿瘤特异性 T 细胞。
Cytotherapy. 2023 Jul;25(7):718-727. doi: 10.1016/j.jcyt.2023.03.014.
3
A first-in-human study of the fibroblast activation protein-targeted, 4-1BB agonist RO7122290 in patients with advanced solid tumors.
一项在晚期实体瘤患者中进行的成纤维细胞激活蛋白靶向 4-1BB 激动剂 RO7122290 的首次人体研究。
Sci Transl Med. 2023 May 10;15(695):eabp9229. doi: 10.1126/scitranslmed.abp9229.
4
The emerging landscape of novel 4-1BB (CD137) agonistic drugs for cancer immunotherapy.新型 4-1BB（CD137）激动剂药物在癌症免疫治疗中的新兴领域。
MAbs. 2023 Jan-Dec;15(1):2167189. doi: 10.1080/19420862.2023.2167189.
5
Site-Specific Antibody Assembly on Nanoparticles via a Versatile Coating Method for Improved Cell Targeting.通过一种通用的涂层方法将抗体组装到纳米颗粒上，实现针对特定部位的抗体组装，从而提高细胞靶向性。
Adv Sci (Weinh). 2023 Mar;10(9):e2206546. doi: 10.1002/advs.202206546. Epub 2023 Jan 25.
6
Unlocking the potential of agonist antibodies for treating cancer using antibody engineering.利用抗体工程技术挖掘激动型抗体治疗癌症的潜力。
Trends Mol Med. 2023 Jan;29(1):48-60. doi: 10.1016/j.molmed.2022.09.012. Epub 2022 Nov 4.
7
Combination Nivolumab, CD137 Agonism, and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma.纳武利尤单抗联合 CD137 激动剂和肿瘤浸润淋巴细胞过继细胞疗法治疗转移性黑色素瘤患者。
Clin Cancer Res. 2022 Dec 15;28(24):5317-5329. doi: 10.1158/1078-0432.CCR-22-2103.
8
CD137 agonist potentiates the abscopal efficacy of nanoparticle-based photothermal therapy for melanoma.CD137激动剂增强基于纳米颗粒的光热疗法对黑色素瘤的远隔效应。
Nano Res. 2022 Mar;15(3):2300-2314. doi: 10.1007/s12274-021-3813-1. Epub 2021 Oct 12.
9
Anti-Fn14-Conjugated Prussian Blue Nanoparticles as a Targeted Photothermal Therapy Agent for Glioblastoma.抗Fn14共轭普鲁士蓝纳米颗粒作为胶质母细胞瘤的靶向光热治疗剂
Nanomaterials (Basel). 2022 Aug 1;12(15):2645. doi: 10.3390/nano12152645.
10
Interstitial Photothermal Therapy Generates Durable Treatment Responses in Neuroblastoma.间质光热疗法可持久缓解神经母细胞瘤。
Adv Healthc Mater. 2022 Oct;11(20):e2201084. doi: 10.1002/adhm.202201084. Epub 2022 Aug 18.